Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | NPC1 | O15118 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | CDK1 | P06493 | 18/20 | 0.76 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.76 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.68 |
| ▸ | CDK2 | P24941 | 5/20 | 0.68 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.68 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.68 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.67 |
| ▸ | CLK2 | P49760 | 1/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.67 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.67 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.67 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17450186 | 0.91 | TDP1 (0.64) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL3298667 | 0.89 | CDK1 (0.63) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL3295958 | 0.89 | CDK2 (0.68) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL17450180 | 0.89 | TDP1 (0.61) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL3299543 | 0.88 | CDK2 (0.70) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL3295975 | 0.87 | CDK2 (0.66) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL1400442 | 0.85 | CDK1 (1.00) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL4484470 | 0.85 | CDK1 (0.64) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL3302791 | 0.84 | CDK2 (0.63) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL3300764 | 0.84 | CDK2 (0.65) | TDP1KDM4ENPC1MAPTCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10561661-B2 | Purine derivative compounds for medical use | MANROS THERAPEUTICS (FR) | 2020-02-18 | — | — | US | disclosed |
| US-10561661-B2 | Purine derivative compounds for medical use | MANROS THERAPEUTICS (FR) | 2020-02-18 | — | — | US | disclosed |
| US-10519160-B2 | Imaging agents for neural flux | THE GENERAL HOSPITAL CORPORATION (US) | 2019-12-31 | — | — | US | disclosed |
| EP-2907514-B1 | Purine derivative compounds for medical use | MANROS THERAPEUTICS (FR) | 2019-10-23 | — | — | EP | disclosed |
| EP-2907514-B1 | Purine derivative compounds for medical use | MANROS THERAPEUTICS (FR) | 2019-10-23 | — | — | EP | disclosed |
| WO-2016011394-A1 | IMAGING AGENTS FOR NEURAL FLUX | THE GENERAL HOSPITAL CORPORATION (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20150320753-A1 | PURINE DERIVATIVE COMPOUNDS FOR MEDICAL USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | disclosed |
| US-20150320753-A1 | PURINE DERIVATIVE COMPOUNDS FOR MEDICAL USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | disclosed |
| US-20150320753-A1 | PURINE DERIVATIVE COMPOUNDS FOR MEDICAL USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | disclosed |
| EP-2907514-A1 | Purine derivative compounds for medical use | Manros Therapeutics (FR) | 2015-08-19 | — | — | EP | disclosed |
| CN-1675213-A | Novel purine derivatives | CYCLACEL LTD (GB) | 2005-09-28 | — | — | CN | disclosed |
| CN-1675211-A | New purine derivatives | CYCLACEL LTD (GB) | 2005-09-28 | — | — | CN | disclosed |
| EP-1399446-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LTD (GB) | 2005-08-03 | — | — | EP | disclosed |
| EP-1534708-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Cyclacel Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| EP-1529047-A2 | NEW PURINE DERIVATIVES | Cyclacel Limited (GB) | 2005-05-11 | — | — | EP | disclosed |
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
| EP-1399446-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2004016612-A2 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004016613-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003002565-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE N THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320753-A1 | PURINE DERIVATIVE COMPOUNDS FOR MEDICAL USE | MSR1, TPMT, M6PR | TDP1 1645/4885KDM4E 2872/4885NPC1 752/4885 |
| US-10561661-B2 | Purine derivative compounds for medical use | MSR1, TPMT, M6PR | TDP1 1645/4885KDM4E 2872/4885NPC1 752/4885 |
| US-10519160-B2 | Imaging agents for neural flux | SLC18A2, SLC18A3, PMP22 | TDP1 1230/4885KDM4E 4777/4885NPC1 31/4885 |
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | TYMP, PNP, IMPDH1 | TDP1 389/4885KDM4E 989/4885NPC1 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.